-
Je něco špatně v tomto záznamu ?
Functionally selective and biased agonists of muscarinic receptors
A. Randáková, J. Jakubík
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- agonisté muskarinových receptorů farmakologie MeSH
- lidé MeSH
- receptory muskarinové účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Disruption of cholinergic signalling via muscarinic receptors is associated with various pathologies, like Alzheimer's disease or schizophrenia. Selective muscarinic agonists possess therapeutic potential in the treatment of diabetes, pain or Sjögren's syndrome. The orthosteric binding site of all subtypes of the muscarinic receptor is structurally identical, making the development of affinity-based selective agonists virtually impossible. Some agonists, however, are functionally selective; they activate only a subset of receptors or signalling pathways. Others may stabilise specific conformations of the receptor leading to non-uniform modulation of individual signalling pathways (biased agonists). Functionally selective and biased agonists represent a promising approach for selective activation of individual subtypes of muscarinic receptors. In this work we review chemical structures, receptor binding and agonist-specific conformations of currently known functionally selective and biased muscarinic agonists in the context of their intricate intracellular signalling. Further, we take a perspective on the possible use of biased agonists for tissue and organ-specific activation of muscarinic receptors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012381
- 003
- CZ-PrNML
- 005
- 20220506130247.0
- 007
- ta
- 008
- 220425s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.phrs.2021.105641 $2 doi
- 035 __
- $a (PubMed)33951507
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Randáková, Alena $u Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic. Electronic address: alena.randakova@fgu.cas.cz
- 245 10
- $a Functionally selective and biased agonists of muscarinic receptors / $c A. Randáková, J. Jakubík
- 520 9_
- $a Disruption of cholinergic signalling via muscarinic receptors is associated with various pathologies, like Alzheimer's disease or schizophrenia. Selective muscarinic agonists possess therapeutic potential in the treatment of diabetes, pain or Sjögren's syndrome. The orthosteric binding site of all subtypes of the muscarinic receptor is structurally identical, making the development of affinity-based selective agonists virtually impossible. Some agonists, however, are functionally selective; they activate only a subset of receptors or signalling pathways. Others may stabilise specific conformations of the receptor leading to non-uniform modulation of individual signalling pathways (biased agonists). Functionally selective and biased agonists represent a promising approach for selective activation of individual subtypes of muscarinic receptors. In this work we review chemical structures, receptor binding and agonist-specific conformations of currently known functionally selective and biased muscarinic agonists in the context of their intricate intracellular signalling. Further, we take a perspective on the possible use of biased agonists for tissue and organ-specific activation of muscarinic receptors.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a agonisté muskarinových receptorů $x farmakologie $7 D018721
- 650 _2
- $a receptory muskarinové $x účinky léků $7 D011976
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Jakubík, Jan $u Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic. Electronic address: jan.jakubik@fgu.cas.cz
- 773 0_
- $w MED00005744 $t Pharmacological research $x 1096-1186 $g Roč. 169, č. - (2021), s. 105641
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33951507 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130239 $b ABA008
- 999 __
- $a ok $b bmc $g 1789816 $s 1163582
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 169 $c - $d 105641 $e 20210502 $i 1096-1186 $m Pharmacological research $n Pharmacol Res $x MED00005744
- LZP __
- $a Pubmed-20220425